H-D-Lys(Boc)-OtBu.HC

H-D-Lys(Boc)-OtBu.HCl is a cornerstone building block in modern peptide synthesis, specifically engineered for N-terminal extension in solution-phase and convergent peptide assembly strategies. As an orthogonally protected D-amino acid derivative, H-D-Lys(Boc)-OtBu.HCl provides peptide chemists with precise control over the directionality of chain assembly — the free α-amino group serves as the nucleophilic acceptor for coupling reactions, while the Boc-protected ε-amine and OtBu-protected C-terminus remain inert during chain elongation. This makes H-D-Lys(Boc)-OtBu.HCl indispensable for the synthesis of complex peptides, peptide-drug conjugates, and peptidomimetics where regioselective functionalization is critical. The D-configuration of H-D-Lys(Boc)-OtBu.HCl is strategically employed to enhance metabolic stability and proteolytic resistance in peptide therapeutics, a feature that has been successfully exploited in the development of bioactive peptides and peptide-based drug candidates. Furthermore, H-D-Lys(Boc)-OtBu.HCl serves as a key intermediate for preparing Nε-labeled lysine derivatives, including biotinylated lysine probes and chromophore- or fluorophore-conjugated lysine building blocks for biological imaging and assay development.

Product Parameters

Why Cosperpharm?

When your peptide synthesis campaign demands orthogonally protected building blocks with precise stereochemical control, Cosperpharm delivers H-D-Lys(Boc)-OtBu.HCl with the analytical rigor, documentation depth, and supply flexibility that pharmaceutical and biotech customers require.

Stereochemical integrity is non-negotiable. The D-configuration of H-D-Lys(Boc)-OtBu.HCl is critical for conferring proteolytic resistance to peptide therapeutics — any racemization during synthesis or storage compromises the biological activity and metabolic stability of your final peptide. Cosperpharm’s analytical release protocol includes chiral HPLC verification, optical rotation measurement, and enantiomeric excess determination to ensure that every batch meets stringent stereochemical specifications.

Documentation that supports regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch-specific HPLC purity, chromatographic traceability, and residual solvent data. For customers preparing IND or NDA filings for peptide therapeutics, Cosperpharm provides DMF-ready documentation packages, stability summaries, and custom quality agreements upon request.

Flexible supply across all development stages. Cosperpharm supplies H-D-Lys(Boc)-OtBu.HCl from 1g–50g quantities for research and process development, to 100g–500g batches for pilot production, to kilogram-scale lots for commercial peptide manufacturing. R&D samples ship within 5–7 business days; bulk orders ship within 2–3 weeks.

Technical support for the full synthetic cascade. Our peptide chemistry team can advise on coupling conditions, deprotection strategies, and compatibility with various peptide synthesis platforms — because we have extensive experience with this orthogonal protection system across multiple manufacturing campaigns.

Global reach with transparent pricing. Cosperpharm ships to pharmaceutical manufacturers, CROs, and research laboratories worldwide, with full customs documentation included. Volume discounts apply at larger scales, and we communicate lead times upfront — no hidden fees, no unexpected delays.

Product Advantages

 Orthogonal Protection for Regioselective Synthesis

H-D-Lys(Boc)-OtBu.HCl features a carefully designed orthogonal protection strategy: the free α-amine (as HCl salt) is available for coupling, the ε-amine is protected by Boc, and the C-terminus is protected by OtBu. Both protecting groups are acid-labile, enabling simultaneous global deprotection in a single step under acidic conditions — significantly reducing processing time and simplifying workup.

 D-Configuration for Proteolytic Resistance

The D-configuration at the α-carbon is a strategic feature of H-D-Lys(Boc)-OtBu.HCl that confers resistance to proteolytic enzymes. Peptides incorporating D-amino acids exhibit enhanced metabolic stability and prolonged half-life in vivo — a property that has been successfully exploited in the development of peptide therapeutics and bioactive peptide probes.

 Hydrochloride Salt Form for Enhanced Handling

The hydrochloride salt form of H-D-Lys(Boc)-OtBu.HCl offers critical practical advantages: improved crystallinity for accurate weighing, enhanced solubility in polar organic solvents commonly used in peptide coupling reactions, and superior long-term storage stability when stored at –20°C under recommended conditions.

 Versatile Building Block for Multiple Applications

H-D-Lys(Boc)-OtBu.HCl serves as the essential building block for synthesizing Nε-labeled lysine derivatives, including biotinylated lysine probes for streptavidin-based detection systems, and chromophore- or fluorophore-conjugated lysine derivatives for fluorescent labeling, FRET-based assays, and biological imaging applications.

 Dual-Use: Peptide Synthesis and Probe Development

Cosperpharm supplies H-D-Lys(Boc)-OtBu.HCl for both peptide synthesis applications (solution-phase and convergent fragment condensation) and specialized probe development (biotinylated lysine derivatives, fluorescent labeling) — with consistent quality and batch-to-batch reproducibility across all applications.

 Product Quality Assurance

Cosperpharm has established a comprehensive quality assurance system for H-D-Lys(Boc)-OtBu.HCl that meets the rigorous expectations of both peptide synthesis and pharmaceutical research applications:

Thorough analytical characterization. Each batch undergoes multi-technique analytical release testing: HPLC purity verification, optical rotation measurement ([α]₂₀/D) for stereochemical confirmation, appearance verification (crystalline powder), water content determination (Karl Fischer), residual solvent analysis (GC), and where applicable, ¹H NMR and MS confirmation of molecular identity. Chiral HPLC is employed to verify enantiomeric purity.

Full batch traceability with retention samples. From raw material procurement through synthesis, purification, drying, and final packaging, every step is fully documented and traceable. Each batch receives a unique lot number with sufficient retention samples maintained in accordance with Cosperpharm quality procedures.

Stability monitoring program. Cosperpharm conducts ongoing stability studies under recommended storage conditions (–20°C), with accelerated stability studies conducted on representative batches. Stability summaries are available to support customer regulatory submissions.

Documentation ready for regulatory submission. Every shipment includes a Certificate of Analysis (COA) with batch-specific purity and characterization data, a Material Safety Data Sheet (SDS), and customs documentation for international delivery. For customers preparing IND or NDA filings, Cosperpharm provides DMF-ready documentation packages, method validation reports, stability data, and custom quality agreements upon request.

Customer-initiated quality audits. Qualified customers are welcome to audit Cosperpharm's manufacturing, quality control, and documentation facilities. Please contact our regulatory team to schedule an audit.

 Contact Us